Dompe U.S.

3 articles with Dompe U.S.

• 

  A Look at the Top 20 Most Expensive Drugs in the U.S.

  2/14/2020

  These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.

• Dompé announces first treatment with Oxervate™ eye drops (cenegermin-bkbj), for neurotrophic keratitis (NK)

  1/3/2019

  Now available through Accredo, Oxervate is the first-in-class recombinant human nerve growth factor (rhNGF) and holds the potential to completely heal NK.

• Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

  8/23/2018

  Oxervate is the first-ever application of a human nerve growth factor as drug or treatment, and is the first-ever topical biologic medication approved in ophthalmology.